| Year |
Citation |
Score |
| 2015 |
Chen L, Du-Cuny L, Moses S, Dumas S, Song Z, Rezaeian AH, Lin HK, Meuillet EJ, Zhang S. Novel inhibitors induce large conformational changes of GAB1 pleckstrin homology domain and kill breast cancer cells. Plos Computational Biology. 11: e1004021. PMID 25569504 DOI: 10.1371/Journal.Pcbi.1004021 |
0.792 |
|
| 2013 |
Meuillet EJ, Moses SA, Jandova J, Mash EA, Zhang S. Abstract 5563: Targeting the PH domain of TIAM1 to inhibit prostate cancer metastasis. Cancer Research. 73: 5563-5563. DOI: 10.1158/1538-7445.Am2013-5563 |
0.755 |
|
| 2012 |
Meuillet EJ, Moses SA, Lucero-Acuna A, Guzman R, Jeffrey J, Pagel M. Abstract 3752: Nanoparticles delivery of a novel AKT/PDK1 inhibitor inhibits pancreatic cancer tumor growth Cancer Research. 72: 3752-3752. DOI: 10.1158/1538-7445.Am2012-3752 |
0.785 |
|
| 2012 |
Beyer TE, Smith RM, Song Z, Gokhale V, Moses SA, Meuillet EJ. Abstract 2835: Discovery of novel inhibitors for ECT2 as a novel therapeutic strategy for lung cancer Cancer Research. 72: 2835-2835. DOI: 10.1158/1538-7445.Am2012-2835 |
0.737 |
|
| 2012 |
Dumas S, Du-Cuny L, Moses S, Song Z, Zhang S, Meuillet EJ. Abstract 2166: In silico identification and biological evaluation of potent small molecule inhibitors targeting GAB1 pleckstrin homology domain Cancer Research. 72: 2166-2166. DOI: 10.1158/1538-7445.Am2012-2166 |
0.802 |
|
| 2011 |
Ahad AM, Zuohe S, Du-Cuny L, Moses SA, Zhou LL, Zhang S, Powis G, Meuillet EJ, Mash EA. Development of sulfonamide AKT PH domain inhibitors. Bioorganic & Medicinal Chemistry. 19: 2046-54. PMID 21353784 DOI: 10.1016/J.Bmc.2011.01.049 |
0.792 |
|
| 2011 |
Meuillet EJ, Mash EA, Olsen E, Moses SA, Morgan SS. Abstract A242: A novel AKT inhibitor, PH427, prevents UVB-induced signaling in human squamous skin carcinomas. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A242 |
0.762 |
|
| 2010 |
Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, et al. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Molecular Cancer Therapeutics. 9: 706-17. PMID 20197390 DOI: 10.1158/1535-7163.Mct-09-0985 |
0.794 |
|
| 2010 |
Moses SA, Song Z, Du-Cuny L, Powis G, Mash E, Zhang S, Meuillet EJ. Abstract 1559: Targeting the PH domain of Tiam-1 to inhibit breast cancer metastasis Cancer Research. 70: 1559-1559. DOI: 10.1158/1538-7445.Am10-1559 |
0.766 |
|
| 2009 |
Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S. Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorganic & Medicinal Chemistry. 17: 6983-92. PMID 19734051 DOI: 10.1016/J.Bmc.2009.08.022 |
0.732 |
|
| 2009 |
Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, Ihle N, Skillman AG, Zhang S, Mash EA, Powis G, Meuillet EJ. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Research. 69: 5073-81. PMID 19491272 DOI: 10.1158/0008-5472.Can-08-3839 |
0.815 |
|
| 2009 |
Powis G, Moses SA, Zhang S, Du‐Cuny L, Song Z, Herbst R, Jacoby J, Kirkpatrick L, Mash E, Meuillet EJ. Abstract B139: Molecular pharmacology and antitumor activity of PHT‐427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B139 |
0.806 |
|
| 2008 |
Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S, Shakalya K, Du-Cuny L, Berggren M, Ali MA, Jana U, Ihle N, Moses S, Franklin C, Narayan S, et al. Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Molecular Cancer Therapeutics. 7: 2621-32. PMID 18790745 DOI: 10.1158/1535-7163.Mct-07-2276 |
0.793 |
|
| Show low-probability matches. |